3,0
21. Dez. 2016
Ehemaliger Mitarbeiter
Port Washington, NY
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Great technology build on science
Kontras
Upper management ruled by Danaher and several at the top making too many decisions without truly knowing the business. Outside of the Biopharm division, minimal investment, only running the business for cash, most focused on cost cutting.